Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36988617.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0393.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[18F]fluoroestradiol (FES) PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors estrogen receptor blockade and posttreatment release. See related article by Iqbal et al., p. 2075.
Medical subject headings
- Breast Neoplasms